Announcement on Voluntary Disclosure of the Completion of the First Subject Enrollment in Phase III Clinical Trial of FDA018 Antibody-drug Conjugate for the Treatment of Triple-negative Breast Cancer
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment